Cormorant Asset Management, LP and Bihua Chen filed Amendment No. 5 to a Schedule 13G on November 16, 2026, disclosing a combined beneficial ownership of 800,000 Common Shares of Bright Minds Biosciences Inc., a clinical-stage bioscience company headquartered in Chicago, Illinois.
Key Highlights
- Reporting persons: Cormorant Asset Management, LP (a Delaware limited partnership and investment adviser) and Bihua Chen jointly filed this ownership statement.
- Shares reported: 800,000 Common Shares of Bright Minds Biosciences Inc. (CUSIP 10919W405) are reported as beneficially owned by each reporting person.
- Percent of class: The 800,000 shares represent 8.11% of outstanding Common Shares, according to the filing.
- Voting and dispositive power: Both reporting persons report 0 shares with sole voting or sole dispositive power, and 800,000 shares with shared voting and shared dispositive power.
- Shares outstanding basis: The percentage was calculated using 9,864,061 Common Shares outstanding as of August 13, 2026, per the issuer's disclosure.
- Dividend rights: The filing states that Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or proceeds from the sale of more than 5% of the shares.
- Event date: The date of the event requiring this filing was September 30, 2026.
Cormorant Asset Management Discloses 8.11% Stake in Bright Minds Biosciences
According to the filing, Cormorant Asset Management, LP serves as investment adviser to certain funds referred to as the "Cormorant Funds," which directly hold the 800,000 Common Shares being reported. Bihua Chen, identified as Managing Member, is also named as a reporting person with respect to the same shares held by those funds. Bright Minds Biosciences Inc., the issuer, is headquartered at 400 N Aberdeen Street, Suite 900, Chicago, IL 60642 and operates in the bioscience sector.
The filing notes that the percentage of class, 8.11%, was derived from a share count of 9,864,061 Common Shares outstanding as of August 13, 2026, which was referenced from the issuer's Management Discussion and Analysis attached as Exhibit 99.2 to a Report of Foreign Private Issuer filed with the SEC on August 17, 2026. The filing further states that Cormorant Global Healthcare Master Fund, LP, one of the Cormorant Funds, holds the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the shares.
The filing includes a certification stating that, to the best of the reporting persons' knowledge and belief, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Both Cormorant Asset Management, LP and Bihua Chen signed the statement on November 16, 2026. The joint filing statement was incorporated by reference from the Schedule 13G filed by the reporting persons on October 22, 2024.
What Was Disclosed
This Amendment No. 5 to Schedule 13G discloses that Cormorant Asset Management, LP and Bihua Chen jointly hold beneficial ownership of 800,000 Common Shares of Bright Minds Biosciences Inc., representing 8.11% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.





Please wait processing your request...